Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxxygender
NCT06832514Phase 4Recruiting
- Sponsor
- Ghent University
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Multicomponent meningococcal B vaccine in meningococcal meningitis (4 arms), sponsored by Ghent University. Primary endpoint: Humoral adaptive immune responses. Started Jan 2025; status: recruiting.
02
Drugs
Multicomponent meningococcal B vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT06832514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832514.